ForthosepatientstheriskofGISTcomingbackismorethan80percent,maybeevenmorethan90,Joensuusaid. "Inlightofthisbackgroundthe92percentoverallsurvivalfigureisfantastic,"hesaid. Thedropoutrateduetoadversesideeffectswashigherinthethree-yeargroup--13.7percentversus7.7percent. ...
The recommended dose of Gleevec is 400 mg/day for the adjuvant treatment of adult patients following complete gross resection of GIST. In clinical trials, one year of Gleevec and three years of Gleevec were studied. In the patient population defined in Study 2, three years of Gleevec is recom...
Pfizer Inc
Patients may be eligible for immediate co-pay savings on their next prescription of GLEEVEC. Eligible patients with private insurance may pay $10 per month Novartis will pay the remaining co-pay, up to $30,000 per calendar year* Encourage your patients to find out if they are eligible to ...
Adult Patients With Adjuvant GIST The recommended dose of Gleevec is 400 mg/day for the adjuvant treatment of adult patients following complete gross resection of GIST. In clinical trials, one year of Gleevec and three years of Gleevec were studied. In the patient population defined in Study 2...
Adult Patients With Adjuvant GIST The recommended dose of Gleevec is 400 mg/day for the adjuvant treatment of adult patients following complete gross resection of GIST. In clinical trials, one year of Gleevec and three years of Gleevec were studied. In the patient population defined in Study 2...
Today theNew England Journal of Medicinepublished results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than 1 in 3 CML patients survived five years...